COGT — Cogent Biosciences Share Price
0.000.00%
Last trade - 00:00- $668.34m
- $381.26m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.61 | ||
| Price to Tang. Book | 2.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -101.38% | ||
| Return on Equity | -78.36% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.87 | n/a | n/a | n/a | n/a | n/a | 39.18 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Directors
- Peter Harwin NEC (35)
- Andrew Robbins PRE (45)
- John Green CFO (40)
- Evan Kearns OTH (40)
- Jessica Sachs OTH (46)
- Chris Cain IND (37)
- Karen Ferrante IND (63)
- Arlene Morris IND (69)
- Matthew Ros IND (55)
- Todd Shegog IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 10th, 2014
- Public Since
- March 29th, 2018
- No. of Shareholders
- 4
- No. of Employees
- 205
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 113,856,454
- Address
- 275 Wyman Street, 3Rd Floor, WALTHAM, 02451
- Web
- https://www.cogentbio.com/
- Phone
- +1 6179455576
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for COGT
Cogent Biosciences Inc Annual Shareholders Meeting
Q2 2025 Cogent Biosciences Inc Earnings Release
Similar to COGT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Cogent Biosciences share price?
As of Today at 20:01 UTC, shares in Cogent Biosciences are trading at $5.87. This share price information is delayed by 15 minutes.
How has the Cogent Biosciences share price performed this year?
Shares in Cogent Biosciences last closed at $5.87 and the price had moved by -19.48% over the past 365 days. In terms of relative price strength the Cogent Biosciences share price has underperformed the S&P500 Index by -27.39% over the past year.
What are the analyst and broker recommendations for Cogent Biosciences?
The overall consensus recommendation for Cogent Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cogent Biosciences dividend yield?
Cogent Biosciences does not currently pay a dividend.
Does Cogent Biosciences pay a dividend?
Cogent Biosciences does not currently pay a dividend.
When does Cogent Biosciences next pay dividends?
Cogent Biosciences does not currently pay a dividend.
How do I buy Cogent Biosciences shares?
To buy shares in Cogent Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cogent Biosciences?
As of the previous close price of $5.87, shares in Cogent Biosciences had a market capitalisation of $668.34m.
Where are Cogent Biosciences shares listed?
Here are the trading details for Cogent Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: COGT
What kind of share is Cogent Biosciences?
Based on an overall assessment of its quality, value and momentum Cogent Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cogent Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Cogent Biosciences is $16.10. That is 174.28% above the last closing price of $5.87.
Analysts covering Cogent Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$2.19 for the next financial year.
Find out moreWhat is the trend in the Cogent Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cogent Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -49.69%.
As of the last closing price of $5.87, shares in Cogent Biosciences were trading -32.68% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cogent Biosciences PE Ratio?
The Cogent Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.87.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cogent Biosciences?
Cogent Biosciences' management team is headed by:
- Peter Harwin - NEC
- Andrew Robbins - PRE
- John Green - CFO
- Evan Kearns - OTH
- Jessica Sachs - OTH
- Chris Cain - IND
- Karen Ferrante - IND
- Arlene Morris - IND
- Matthew Ros - IND
- Todd Shegog - IND